Session » SpA Including PsA – Treatment Poster I
- 10:30AM-12:30PM
-
Abstract Number: 0582
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
- 10:30AM-12:30PM
-
Abstract Number: 0587
Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
- 10:30AM-12:30PM
-
Abstract Number: 0595
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
- 10:30AM-12:30PM
-
Abstract Number: 0602
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
- 10:30AM-12:30PM
-
Abstract Number: 0591
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
- 10:30AM-12:30PM
-
Abstract Number: 0597
Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
- 10:30AM-12:30PM
-
Abstract Number: 0600
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
- 10:30AM-12:30PM
-
Abstract Number: 0598
Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 0580
Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis
- 10:30AM-12:30PM
-
Abstract Number: 0606
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
- 10:30AM-12:30PM
-
Abstract Number: 0585
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
- 10:30AM-12:30PM
-
Abstract Number: 0601
Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
- 10:30AM-12:30PM
-
Abstract Number: 0584
Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
- 10:30AM-12:30PM
-
Abstract Number: 0590
Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
- 10:30AM-12:30PM
-
Abstract Number: 0605
Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
- 10:30AM-12:30PM
-
Abstract Number: 0596
Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation
- 10:30AM-12:30PM
-
Abstract Number: 0583
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 0586
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
- 10:30AM-12:30PM
-
Abstract Number: 0594
Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
- 10:30AM-12:30PM
-
Abstract Number: 0604
Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
- 10:30AM-12:30PM
-
Abstract Number: 0599
Sex- related Differences in Efficacy of Biologics in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
- 10:30AM-12:30PM
-
Abstract Number: 0588
Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 0603
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
- 10:30AM-12:30PM
-
Abstract Number: 0592
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
- 10:30AM-12:30PM
-
Abstract Number: 0589
Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials